Amolyt Pharma
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting
LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society’s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021.
(0)
Four abstracts accepted as poster presentations for the Endocrine Society s Annual Meeting
LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021.
Amolyt will present preliminary data from its Phase 1 clinical trial evaluating AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, in addition to two abstracts detailing a retrospective natural history study of chronic hypoparathyroidism. Amolyt will also present preclinical data for AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism. Details of the abstracts are as follows:
The Voice and
America’s Got Talent are any indication, there are many extremely talented people out there who could become huge successes if presented with the right opportunity. This is no less the case in science, with thousands of extremely bright individuals quietly toiling away in their mentors’ labs as they await the chance to establish research programs of their own.
Fortunately, initiatives like the NIH’s Lasker Clinical Research Scholars Program exist to boost promising young researchers on to the next stage of their careers. Every year, the Lasker program allows a small group of early stage physician-scientists to establish their own labs at the NIH and carry out independent clinical research there for at least five years.